Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 04:00PM ET
4.59
Dollar change
-0.19
Percentage change
-3.97
%
IndexRUT P/E- EPS (ttm)-0.51 Insider Own19.16% Shs Outstand116.86M Perf Week-11.73%
Market Cap537.63M Forward P/E- EPS next Y-0.38 Insider Trans2.25% Shs Float94.69M Perf Month-12.90%
Income-50.62M PEG- EPS next Q-0.16 Inst Own59.40% Short Float5.44% Perf Quarter-23.37%
Sales34.16M P/S15.74 EPS this Y-14.95% Inst Trans0.72% Short Ratio11.24 Perf Half Y-10.53%
Book/sh2.69 P/B1.71 EPS next Y35.67% ROA-12.03% Short Interest5.15M Perf Year31.14%
Cash/sh0.74 P/C6.18 EPS next 5Y- ROE-15.43% 52W Range3.14 - 6.72 Perf YTD-25.61%
Dividend Est.- P/FCF768.04 EPS past 5Y- ROI-15.04% 52W High-31.65% Beta-0.08
Dividend TTM- Quick Ratio4.11 Sales past 5Y13.92% Gross Margin44.37% 52W Low46.18% ATR (14)0.22
Dividend Ex-Date- Current Ratio4.11 EPS Y/Y TTM-121.77% Oper. Margin-202.63% RSI (14)28.77 Volatility3.80% 4.32%
Employees106 Debt/Eq0.08 Sales Y/Y TTM-3.34% Profit Margin-148.16% Recom1.00 Target Price10.00
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-292.72% Payout- Rel Volume2.32 Prev Close4.78
Sales Surprise-35.38% EPS Surprise1.75% Sales Q/Q-86.36% EarningsMar 20 AMC Avg Volume457.85K Price4.59
SMA20-12.13% SMA50-15.29% SMA200-13.80% Trades Volume1,064,099 Change-3.97%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Initiated RBC Capital Mkts Outperform $6
Apr-21-23Initiated The Benchmark Company Buy $8
Apr-13-23Initiated Craig Hallum Buy $10
Feb-22-23Initiated Cowen Outperform $10
Feb-13-23Initiated H.C. Wainwright Buy $11
Dec-20-22Initiated Truist Buy $10
Dec-16-22Initiated Credit Suisse Outperform $13
Nov-29-22Initiated SVB Leerink Outperform $6
Nov-28-22Initiated Stifel Buy $12
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
Feb-26-24 08:00AM
08:00AM Loading…
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
Oct-31-23 04:28PM
02:32PM Loading…
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
07:00AM Loading…
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUSTAFSON KURT AExecutive VP, Finance and CFOApr 08 '24Sale5.276,95436,648176,697Apr 09 06:38 PM
Berkman Charles SChief Legal OfficerApr 08 '24Sale5.276,95436,648292,617Apr 09 06:37 PM
GUSTAFSON KURT AExecutive VP, Finance & CFOApr 01 '24Sale5.4611,84964,696170,110Apr 02 06:30 PM
FOEHR MATTHEW WPresident and CEOMar 27 '24Option Exercise3.72243,613907,0233,152,416Mar 29 04:52 PM
FOEHR MATTHEW WPresident and CEOMar 22 '24Buy5.19225,0001,167,7502,908,803Mar 25 07:07 AM
FOEHR MATTHEW WChief Executive OfficerDec 12 '23Buy5.05200,0001,010,0002,645,442Dec 13 03:25 PM
FOEHR MATTHEW WPresident and CEONov 10 '23Buy4.2795,000405,5172,427,919Nov 13 08:00 AM
FOEHR MATTHEW WPresident and CEOAug 14 '23Buy5.4845,000246,6002,332,919Aug 15 04:56 PM
FOEHR MATTHEW WChief Executive OfficerJun 09 '23Buy4.52115,000519,8002,574,009Jun 12 04:47 PM
HIGGINS JOHN LDirectorMay 23 '23Option Exercise3.689,00033,1202,471,686May 25 04:45 PM
HIGGINS JOHN LDirectorMay 23 '23Sale4.059,00036,4502,462,686May 25 04:45 PM
HIGGINS JOHN LDirectorMay 19 '23Option Exercise3.681,0003,6802,463,686May 23 04:12 PM
HIGGINS JOHN LDirectorMay 19 '23Sale4.051,0004,0502,462,686May 23 04:12 PM
HIGGINS JOHN LDirectorMay 18 '23Option Exercise3.6850,000184,0002,512,686May 19 05:03 PM
HIGGINS JOHN LDirectorMay 18 '23Sale3.8950,000194,5002,462,686May 19 05:03 PM
FOEHR MATTHEW WChief Executive OfficerMay 12 '23Buy3.40440,0001,496,0002,438,414May 15 04:02 PM